Mohammed A. Assmairan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammed A. Assmairan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ali Ahmad Al-Omari
Department of Special Surgery, Division of Orthopedic Surgery, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan
1 shared publication - Khaldoon Alawneh
Department of Internal Medicine, Division of Rheumatology, School of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan
1 shared publication - Mahmoud Husni Ayesh (Haj Yousef)
Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan
1 shared publication - Moh'D Al Barbarawi
King Abdullah University Hospital, Amman-Ramtha Road, Irbid, 22110 Outside of the US Jordan
1 shared publication - Mohammad Alfawareh
Department of Spine Surgery, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia
1 shared publication Mohammad D. Fawareh
Ibn Alhaytham Hospital, Tela' Al Ali, Amman, 11953 Outside of the US Jordan
1 shared publication
Latest Publications
- Open Access
- 29 December 2016
- Published by Springer Nature in Scoliosis and Spinal Disorders
- Vol. 11 (1) , 47
Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma
This was a prospective study to evaluate the effect of multilevel vertebral augmentation in addition to conventional therapy in multiple myeloma patients. We treated 27 patients, whom were recently diagnosed to have multiple myeloma by two ways of treatment. Thirteen patients (group I) were treated with conventional therapy and 14 patients (group II) with adding vertebroplasty and kyphoplasty. Patients were evaluated pre-treatment and at half, one, two and 3-years post-treatment by using Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS). Mean values of ODI, SS and SINS were 31.9 (63.8%), 4.3 and 13.8 for group I and 33.2 (66.4%), 4.6 and 12.8 for group II before starting treatment. Group II showed improvement better than group I at all follow-up intervals with best results at first 6 months. P-values at the end of the study were ODI = 0.047, SS = 0.180 and SINS = 0.002. Mortality rates were equal of both groups (four patients of each group). Adding vertebral augmentation to conventional therapy improves multiple myeloma patients’ quality of life, but didn’t affect the mortality rate.
- 29 December 2016
- Published by Springer Nature in Scoliosis and Spinal Disorders
- Vol. 11 (1) , 47
Open AccessComparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma
This was a prospective study to evaluate the effect of multilevel vertebral augmentation in addition to conventional therapy in multiple myeloma patients. We treated 27 patients, whom were recently diagnosed to have multiple myeloma by two ways of treatment. Thirteen patients (group I) were treated with conventional therapy and 14 patients (group II) with adding vertebroplasty and kyphoplasty. Patients were evaluated pre-treatment and at half, one, two and 3-years post-treatment by using Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS). Mean values of ODI, SS and SINS were 31.9 (63.8%), 4.3 and 13.8 for group I and 33.2 (66.4%), 4.6 and 12.8 for group II before starting treatment. Group II showed improvement better than group I at all follow-up intervals with best results at first 6 months. P-values at the end of the study were ODI = 0.047, SS = 0.180 and SINS = 0.002. Mortality rates were equal of both groups (four patients of each group). Adding vertebral augmentation to conventional therapy improves multiple myeloma patients’ quality of life, but didn’t affect the mortality rate.